MedTrace Logo

Phase II Trial of Ontak With Metastatic Melanoma

NCT00299689 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2014-09-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether ONTAK is an effective treatment in patients with Stage IV Melanoma

Conditions

  • Malignant Melanoma

Interventions

DRUG

Denileukin diftitox

12 mcg/kg IV (in vein) over 30 minutes on days 1 through 4 of each 21 day cycle for 4 cycles.

Sponsors & Collaborators

  • University of Louisville

    collaborator OTHER

  • James Graham Brown Cancer Center

    lead OTHER

Principal Investigators

  • Jason Chesney, MD, PhD · University of Louisville

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00299689 on ClinicalTrials.gov